AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33454714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 36177501 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil daily
Number of subjects: 60
Study 36177501 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil 2 hours before sexual relations twice a week
Number of subjects: 60
Study 36177501 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil daily + 15 mg tadalafil 2 hours before sexual relations twice a week
Number of subjects: 60
Study 33730421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self‐expandable metal stents (FCSEMS)
Number of subjects: 30
Study 33730421 — intervention group
Group type: COMPARATOR
Intervention: Multiple plastic stents (MPS)
Number of subjects: 30
Study 32007823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (ACEI)
Number of subjects: 91
Study 32007823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 32007823 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitor beyond 1 year
Number of subjects: 91
Study 32007823 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in index of microcirculatory resistance from baseline to 1 year
Number of subjects: 91
Study 33923235 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% trehalose
Number of subjects: 12
Study 33923235 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% glucose
Number of subjects: 12
Study 33923235 — intervention group
Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 12
Study 35905507 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 63
Study 35905507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 32725573 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate associated with paracetamol
Number of subjects: 47
Study 32725573 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 47
Study 32755802 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) targeting the ventral anterior limb of the internal capsule
Number of subjects: 14
Study 32755802 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study 35378408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapist
Number of subjects: 147
Study 35378408 — intervention group
Group type: COMPARATOR
Intervention: Hand surgeons
Number of subjects: 147
Study 35378408 — intervention group
Group type: EXPERIMENTAL
Intervention: Three hand therapists
Number of subjects: 147
Study 32335343 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 64
Study 32335343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 35690690 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD before treatment
Number of subjects: 46
Study 35690690 — intervention group
Group type: EXPERIMENTAL
Intervention: ISS
Number of subjects: 46
Study 35690690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 33727208 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy before IVF (Group I)
Number of subjects: 171
Study 33727208 — intervention group
Group type: COMPARATOR
Intervention: Immediate IVF (Group II)
Number of subjects: 171
Study 36042674 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 22
Study 36042674 — intervention group
Group type: COMPARATOR
Intervention: Elective surgery
Number of subjects: 22
Study 34656948 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed anthropometric equation using calf circumference and other variables
Number of subjects: 1262
Study 34656948 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed anthropometric equation
Number of subjects: 1262
Study 34656948 — intervention group
Group type: COMPARATOR
Intervention: Previously reported equations
Number of subjects: 1262
Study 35100279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride (2%) injected intradermally using MicronJet600 device (MJ-Lido)
Number of subjects: 102
Study 35100279 — intervention group
Group type: COMPARATOR
Intervention: No injection (No pretreatment)
Number of subjects: 102
Study 33032883 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free arm (Basiliximab + Tacrolimus + Azathioprine)
Number of subjects: 104
Study 33032883 — intervention group
Group type: COMPARATOR
Intervention: Steroid arm (Steroid + Tacrolimus + Azathioprine)
Number of subjects: 104
Study 33032883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 104
Study 32863109 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left temporoparietal area (LTA) and cathodal tDCS over the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 24
Study 32863109 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (sham tDCS)
Number of subjects: 24
Study 34133243 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSAIC program (classroom intervention)
Number of subjects: 558
Study 34133243 — intervention group
Group type: COMPARATOR
Intervention: Typical practice control group
Number of subjects: 558
Study 34133243 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSAIC program (target children)
Number of subjects: 558
Study 34133243 — intervention group
Group type: COMPARATOR
Intervention: Typical practice control group (target children)
Number of subjects: 558
Study 32672062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 21
Study 32672062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 34275239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang (JHWK) (14 days of quadruple therapy + 30 days of JHWK)
Number of subjects: 1054
Study 34275239 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (14 days)
Number of subjects: 1054
Study 34275239 — intervention group
Group type: EXPERIMENTAL
Intervention: All enrolled patients post-treatment
Number of subjects: 1054
Study 34275239 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group post-treatment
Number of subjects: 1054
Study 34275239 — intervention group
Group type: COMPARATOR
Intervention: Control group post-treatment
Number of subjects: 1054
Study 34275239 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 1054
Study 32517785 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure self-management (daily home blood pressure monitoring and automated medication reduction via telemonitoring)
Number of subjects: 68
Study 32517785 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study 34116351 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS challenge (1 replicate)
Number of subjects: 500
Study 34116351 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS challenge (2 replicates)
Number of subjects: 500
Study 34116351 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS challenge (0.4 mg/kg)
Number of subjects: 500
Study 34116351 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS challenge (0.1, 0.2, and 0.8 mg/kg)
Number of subjects: 500
Study 34116351 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS challenge (various dosages)
Number of subjects: 500
Study 34409620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal treatment using pure oxybuprocaine gel with adequate lubrication (group G)
Number of subjects: 844
Study 34409620 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ephedrine in addition to oxybuprocaine gel with adequate lubrication (group EG)
Number of subjects: 844
Study 34409620 — intervention group
Group type: COMPARATOR
Intervention: Difficult advancement of the endotracheal tube
Number of subjects: 844
Study 32513518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic testing (guided-care)
Number of subjects: 206
Study 32513518 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 206
Study 35766039 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care combined with optimized insulin injection techniques
Number of subjects: 96
Study 35766039 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional continuous nursing)
Number of subjects: 96
Study 34130395 — intervention group
Group type: EXPERIMENTAL
Intervention: Robenacoxib 2 mg/kg IM
Number of subjects: 12
Study 34130395 — intervention group
Group type: COMPARATOR
Intervention: Saline IM (control)
Number of subjects: 12
Study 35283454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple low calcineurin inhibitor (CNI) regimen
Number of subjects: 123
Study 35283454 — intervention group
Group type: COMPARATOR
Intervention: Standard triple regimen
Number of subjects: 123
Study 35283454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple low CNI regimen
Number of subjects: 123
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyanidins
Number of subjects: 40
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tannic acid
Number of subjects: 40
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringin
Number of subjects: 40
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallic acid
Number of subjects: 40
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Number of subjects: 40
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizic acid
Number of subjects: 40
Study 32241201 — intervention group
Group type: EXPERIMENTAL
Intervention: Paeonol
Number of subjects: 40
Study 32241201 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 40
Study 33878772 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment in the first 24 hours (group 1)
Number of subjects: 87
Study 33878772 — intervention group
Group type: COMPARATOR
Intervention: Caffeine treatment at the 72nd hour (group 2)
Number of subjects: 87
Study 34992346 — intervention group
Group type: EXPERIMENTAL
Intervention: AD-206 (esomeprazole 20 mg or 40 mg + calcium carbonate 600 mg)
Number of subjects: 44
Study 34992346 — intervention group
Group type: COMPARATOR
Intervention: Conventional esomeprazole (Nexium®)
Number of subjects: 44
Study 33080728 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniportal VATS (UVATS)
Number of subjects: 69
Study 33080728 — intervention group
Group type: COMPARATOR
Intervention: Multiportal VATS (MVATS)
Number of subjects: 69
Study 35797000 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill training
Number of subjects: 39
Study 35797000 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater walking therapy
Number of subjects: 39
Study 35797000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 34454358 — intervention group
Group type: COMPARATOR
Intervention: Random synthetic transmit aperture (RSTA) method using a fraction of linear array elements in transmit mode.
Number of subjects: 0
Study 35654466 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard (reactive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Number of subjects: 740
Study 35654466 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty-adjusted (adaptive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Number of subjects: 740
Study 35654466 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with lenalidomide+ixazomib
Number of subjects: 740
Study 35654466 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment with lenalidomide+placebo
Number of subjects: 740
Study 34802955 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 25
Study 34802955 — intervention group
Group type: COMPARATOR
Intervention: Classical music listening (ML)
Number of subjects: 25
Study 32845740 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg galcanezumab (240 mg loading dose)
Number of subjects: 106
Study 32845740 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg galcanezumab
Number of subjects: 106
Study 32845740 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 106
Study 32845740 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study 33899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Free thyroxine (fT4) levels
Number of subjects: 170756
Study 33899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin (TSH) levels
Number of subjects: 170756
Study 33899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to MDD and BD
Number of subjects: 170756
Study 32597373 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge condition (n=40) received daily emails for 24 days highlighting a particular strength, its value, implementation strategies, and a motto.
Number of subjects: 75
Study 32597373 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=35) received daily emails containing only the motto for each strength for 24 days.
Number of subjects: 75
Study 33607813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac plus Lidocaine (30 mg Ketorolac and 2% Lidocaine - adrenaline)
Number of subjects: 128
Study 33607813 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2% Lidocaine - adrenaline)
Number of subjects: 128
Study 33090904 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to biological dust
Number of subjects: 17833
Study 33090904 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to mineral dust
Number of subjects: 17833
Study 33090904 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to metals
Number of subjects: 17833
Study 34267122 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection
Number of subjects: 28
Study 34267122 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 28
Study 34267122 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of cleft lip alone vs cleft lip and palate
Number of subjects: 28
Study 34024693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond Prineo
Number of subjects: 51
Study 34024693 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 51
Study 32102033 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended subscleral tunnel (ESST)
Number of subjects: 40
Study 32102033 — intervention group
Group type: COMPARATOR
Intervention: Conventional subscleral trabeculectomy (SST)
Number of subjects: 40
Study 34873023 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG group (20 mL 0.5% ropivacaine)
Number of subjects: 71
Study 34873023 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (20 mL saline)
Number of subjects: 71
Study 34873023 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG group
Number of subjects: 71
Study 34873023 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 71
Study 32619415 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding intra-annular transcatheter heart valves
Number of subjects: 180
Study 32619415 — intervention group
Group type: COMPARATOR
Intervention: Commercially available transcatheter heart valves
Number of subjects: 180
Study 33806822 — intervention group
Group type: EXPERIMENTAL
Intervention: FACR diet (five days’ carbohydrate < 20% and fat > 60% energy, plus one‐day carbohydrate ≥ 70% energy)
Number of subjects: 8
Study 33806822 — intervention group
Group type: COMPARATOR
Intervention: HCHO diet (carbohydrate > 60% energy; fat < 20% energy)
Number of subjects: 8
Study 32603996 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of moderate-intensity exercise on a cycling ergometer (n = 37)
Number of subjects: 84
Study 32603996 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (n = 47)
Number of subjects: 84
Study 32603996 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of moderate-intensity exercise
Number of subjects: 84
Study 32603996 — intervention group
Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 84
Study 33301926 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (rTSA)
Number of subjects: 99
Study 33301926 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 99
Study 33301926 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (rTSA) in patients aged ≥ 80 years
Number of subjects: 99
Study 33301926 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA) in patients aged ≥ 80 years
Number of subjects: 99
Study 32094159 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0
Study 35711147 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (3 mg/kg)
Number of subjects: 42
Study 35711147 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (4 mg/kg)
Number of subjects: 42
Study 35711147 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (6 mg/kg)
Number of subjects: 42
Study 35711147 — intervention group
Group type: COMPARATOR
Intervention: Reference voriconazole (3 mg/kg)
Number of subjects: 42
Study 35711147 — intervention group
Group type: COMPARATOR
Intervention: Reference voriconazole (4 mg/kg)
Number of subjects: 42
Study 35711147 — intervention group
Group type: COMPARATOR
Intervention: Reference voriconazole (6 mg/kg)
Number of subjects: 42
Study 35711147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 34153141 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC Miller videolaryngoscope
Number of subjects: 140
Study 34153141 — intervention group
Group type: COMPARATOR
Intervention: McGrath MAC size-1 videolaryngoscope
Number of subjects: 140
Study 32574009 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol serum (0.25%, 0.5%, 1.0%)
Number of subjects: 45
Study 32574009 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin cream (0.025%, 0.05%, 0.1%)
Number of subjects: 45
Study 35684089 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (25 g) and Vitamin D3 (4000 IU) before bedtime
Number of subjects: 42
Study 35684089 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (25 g) and Vitamin D3 (4000 IU) after sleeping
Number of subjects: 42
Study 35684089 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (5 g) - Control group
Number of subjects: 42
Study 34639501 — intervention group
Group type: EXPERIMENTAL
Intervention: BJ-400
Number of subjects: 8
Study 34639501 — intervention group
Group type: EXPERIMENTAL
Intervention: BJ-800
Number of subjects: 8
Study 34639501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 34639501 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study 35107694 — intervention group
Group type: EXPERIMENTAL
Intervention: KEEP-P (core PMT Oregon Model methods)
Number of subjects: 175
Study 35107694 — intervention group
Group type: EXPERIMENTAL
Intervention: KEEP-V (integrated KEEP with Filming Interactions to Nurture Development video coaching)
Number of subjects: 175
Study 35107694 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intervention dosage
Number of subjects: 175
Study 33412281 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz AM-tACS targeting the visual cortex
Number of subjects: 7
Study 33412281 — intervention group
Group type: COMPARATOR
Intervention: No artifact rejection method applied
Number of subjects: 7
Study 35318229 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 192
Study 35318229 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 192
Study 35318229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Methotrexate and Adalimumab
Number of subjects: 192
Study 32178640 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist guided internet-delivered cognitive therapy (TG-iConquerFear)
Number of subjects: 246
Study 32178640 — intervention group
Group type: COMPARATOR
Intervention: Augmented treatment as usual (aTAU)
Number of subjects: 246
Study 32178640 — intervention group
Group type: EXPERIMENTAL
Intervention: TG-iConquerFear
Number of subjects: 246
Study 35805372 — intervention group
Group type: COMPARATOR
Intervention: GS + CST
Number of subjects: 362
Study 35805372 — intervention group
Group type: COMPARATOR
Intervention: CST
Number of subjects: 362
Study 35805372 — intervention group
Group type: COMPARATOR
Intervention: GS
Number of subjects: 362
Study 33276704 — intervention group
Group type: COMPARATOR
Intervention: LT4/LT3 combination therapy
Number of subjects: 0
Study 35126618 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐Pueraria targeted preparation + Tuina therapy
Number of subjects: 200
Study 35126618 — intervention group
Group type: COMPARATOR
Intervention: Tuina therapy
Number of subjects: 200
Study 34296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 58
Study 34296979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 32052217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU/day of vitamin D3 supplementation
Number of subjects: 328
Study 32052217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/day of vitamin D3 supplementation
Number of subjects: 328
Study 32052217 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 IU/day of vitamin D3 supplementation
Number of subjects: 328
Study 32052217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 35153118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water spray (0.4 mL per application, twice every hour)
Number of subjects: 104
Study 35153118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold saline spray (0.4 mL per application, twice every hour)
Number of subjects: 104
Study 35153118 — intervention group
Group type: COMPARATOR
Intervention: Control group (water at room temperature, 1-2 mL using a syringe)
Number of subjects: 104
Study 32898082 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vancomycin powder at wound closure
Number of subjects: 583
Study 33094385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold/dry, cold/humid, warm/dry, warm/humid settings
Number of subjects: 50
Study 33094385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffin’ Sticks test battery
Number of subjects: 50